Intismeran Autogene and the Fibonacci Number 34: An Exact 100% Coordinate Fit within the GEIER Programme by Stefan Geier et al., Gerhart-Hauptmann-Straße 6, 83071 Haidholzen

Intismeran Autogene and the Fibonacci Number 34: An Exact 100% Coordinate Fit within the GEIER Programme - A first look

by Stefan Geier et al., Gerhart-Hauptmann-Straße 6, 83071 Haidholzen

Intismeran autogene provides an exact Fibonacci observation: its published maximum capacity of 34 patient-specific neoantigens is identical to the Fibonacci number (F_9=34), giving a numerical proximity of precisely 100%.

Intismeran autogene (V940; formerly mRNA-4157) is an investigational individualized mRNA-based neoantigen therapy designed from the mutational profile and human leukocyte antigen characteristics of an individual patient's tumour. Remarkably, the construct is designed to encode up to 34 patient-specific neoantigens. The integer 34 is simultaneously the ninth Fibonacci number,

F_9=34,

for the convention (F_0=0,;F_1=1). Thus, at the level of the therapy's stated maximal neoantigen capacity, Intismeran autogene exhibits an exact, 100% correspondence with a Fibonacci coordinate. This short analysis examines that observation within the GEIER programme, which explores whether Fibonacci numbers, Lucas numbers and the golden ratio (ϕ) can provide useful structural coordinates across biological systems. The numerical correspondence is exact and therefore requires no approximation. Its biological interpretation, however, must remain substantially more cautious: current evidence does not demonstrate that 34 was selected because of Fibonacci mathematics or that Fibonacci organization causes the therapeutic effect. Intismeran autogene therefore constitutes an interesting exact structural fit and a hypothesis-generating observation, rather than evidence by itself for a universal Fibonacci law.

Keywords: Intismeran autogene; V940; mRNA-4157; Fibonacci; 34; neoantigen; mRNA; cancer immunotherapy; personalized medicine; GEIER programme

Intismeran autogene converts tumour and HLA information into an individualised mRNA construct containing up to 34 selected neoantigens. The ceiling is independently documented; 34=F9 is an exact mathematical identity. The GEIER interpretation is a (well corroborated) prospective hypothesis about design equilibrium, not an established mechanism.

References

1. World Health Organization. Proposed International Nonproprietary Names: List 131. WHO Drug Information 2024; 38: 354 (entry: intismeran autogene). Published Aug 11, 2024.

2. Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 2024; 403: 632–44. doi:10.1016/S0140-6736(23)02268-7.

3. Gainor JF, Patel MR, Weber JS, et al. T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study. Cancer Discov 2024; 14: 2209–23. doi:10.1158/2159-8290.CD-24-0158.

4. Khattak A, Carlino MS, Meniawy T, et al. Intismeran autogene plus pembrolizumab versus pembrolizumab alone in high-risk resected melanoma: 5-year update of the randomised phase IIb KEYNOTE-942 study. J Clin Oncol 2026; published online June 1. doi:10.1200/JCO-26-00835.

5. Merck & Co., Inc.; Moderna, Inc. Merck and Moderna announce phase 3 INTerpath-001 trial of intismeran autogene plus pembrolizumab met endpoints of recurrence-free survival and distant-metastasis-free survival in completely resected stage IIB–IV melanoma. Press release. Aug 19, 2026 (accessed Aug 21, 2026).

6. ClinicalTrials.gov. A phase 3, randomised, double-blind, placebo- and active-comparator-controlled clinical study of adjuvant V940 (mRNA-4157) plus pembrolizumab versus placebo plus pembrolizumab in high-risk stage II–IV melanoma (INTerpath-001). NCT05933577 (accessed Aug 21, 2026).

7. Koshy T. Fibonacci and Lucas numbers with applications. 2nd edn. Hoboken, NJ: Wiley, 2017. doi:10.1002/9781118742327.

8. Geier SA, Geier C, Geier S, et al. “GEIER’s Equations” and “GEIER’s Φ(e) ↔ Φ(α) Equilibrium Programme” with Fibonacci/Lucas extensions (GEIER’s Equations Part 2.1). ResearchGate preprint, 2026. doi:10.13140/RG.2.2.33185.67689.

9. Geier S, Geier-Noehl M. First report: the 20S disc of the tobacco mosaic virus is related to the golden-ratio concept in biology by the Fibonacci number F(9)=34. ResearchGate preprint, 2024. doi:10.13140/RG.2.2.12899.77607.

10. Geier SA, Geier C, Geier S, et al. Fibonacci and Lucas numbers in animal body plans and GEIER’s Equations: revisiting John J Wille’s morphogenesis claims (Part 1). ResearchGate preprint, 2026. doi:10.13140/RG.2.2.25650.67528.

11. Butler PJG, Klug A. Assembly of the particle of tobacco mosaic virus from RNA and disks of protein. Nature New Biol 1971; 229: 47–50. doi:10.1038/newbio229047a0.

12. Douady S, Couder Y. Phyllotaxis as a physical self-organized growth process. Phys Rev Lett 1992; 68: 2098–2101. doi:10.1103/PhysRevLett.68.2098.

13. Jagannathan A. The Fibonacci quasicrystal: case study of hidden dimensions and multifractality. Rev Mod Phys 2021; 93: 045001. doi:10.1103/RevModPhys.93.045001.

14. Swinton J, Ochu E, The MSI Turing’s Sunflower Consortium. Novel Fibonacci and non-Fibonacci structure in the sunflower: results of a citizen science experiment. R Soc Open Sci 2016; 3: 160091. doi:10.1098/rsos.160091.

Additum:

The 34-neoantigen ceiling of intismeran autogene is exactly Fibonacci F9 (and a retro-prospective test of the GEIER programme) – A deepened first look

by Stefan A. Geier*, Caroline Geier, Stephanie Geier, Constantin Geier, Katharina Geier, Nora Blättermann-Goldstein, and Michèle Geier-Noehl**

All authors: Institute for Structuralistic Theory of Sciences Simssee ISTS, Gerhart-Hauptmann-Straße 6, 83071 Haidholzen, Germany, and LMU Munich, Geschwister-Scholl-Platz 1, 80539 Munich, Germany; ^**Dermatologische Klinik der Landeshauptstadt und der Ludwig-Maximilians-Universität LMU München, Thalkirchner Straße 48, 80337 München, Germany;

*To whom correspondence should be addressed: Stefan Geier, Institute for Structuralistic Theory of Sciences Simssee ISTS, Gerhart-Hauptmann-Straße 6, 83071 Haidholzen, Germany, Europe, Blue Planet Earth, email: wissenschaftstheorie.simssee.1@gmail.com
Vers 0.0.0.0

 

One-Sentence Abstract

Intismeran autogene’s independently documented ceiling of 34 patient-specific neoantigens is exactly the ninth Fibonacci number, providing complete arithmetic coordinate agreement and an unusually strong, falsifiable test case for the GEIER Fibonacci–Lucas programme, although neither Fibonacci-based design intent nor causal contribution to efficacy has yet been demonstrated.

Abstract

Intismeran autogene (V940; formerly mRNA-4157) is an individualised mRNA neoantigen therapy whose patient-specific construct can encode up to 34 tumour neoantigens. Thirty-four is exactly the ninth Fibonacci number (F9=34). This externally anchored equality gives 100% descriptive coordinate agreement, with zero absolute error and no scaling, rounding, interpolation, or fitted parameter. The observation is therefore more stringent than a retrospective “near-Fibonacci” comparison and supports Stefan Geier and colleagues’ proposal that Fibonacci and Lucas numbers can be investigated as structural or equilibrium coordinates across biological systems. Its interpretation must nevertheless remain bounded: “up to 34” is a platform ceiling rather than every patient’s realised payload; published sources do not show that 34 was chosen because it is Fibonacci; and clinical efficacy cannot be attributed to the equality. We propose a prospective programme that models cap censoring, compares 34 with neighbouring and sequence-based caps, and measures antigenic coverage, expression, T-cell breadth, immunodominance, stability, and manufacturability. The exact fit is established; its engineering or biological meaning is an open, experimentally tractable question.

 

Structured Abstract

Background — Geier and colleagues have proposed that Fibonacci and Lucas numbers may function as cross-domain structural coordinates. Intismeran autogene is independently described as encoding up to 34 patient-specific neoantigens, creating a direct test of the Fibonacci coordinate F9=34.

Methods — We performed a source-anchored arithmetic audit using WHO nomenclature documentation, peer-reviewed clinical and mechanistic reports, current trial information, and the published Geier preprint corpus. We separated arithmetic identity, source independence, design intent, mechanistic plausibility, and clinical consequence.

Findings — The documented maximum payload is 34 and F9=34; therefore, absolute distance is zero and normalised coordinate agreement is 100.000%, without an adjustable parameter. The same F9 coordinate had previously been emphasised by Geier and Geier-Noehl in the 34-subunit tobacco mosaic virus 20S disc. However, no source establishes Fibonacci-based selection of the intismeran ceiling, and the ceiling does not imply that every product contains 34 neoantigens.

Interpretation — The observation favours the GEIER programme as a disciplined hypothesis generator because it is exact, externally fixed, biologically meaningful, and prospectively testable. It does not yet validate a causal Fibonacci mechanism. Cap-perturbation studies, patient-level payload distributions, realistic null models, and cross-platform replication can distinguish an engineering equilibrium coordinate from coincidence.

Funding — No dedicated external funding is declared in this manuscript draft; this statement must be verified by the submitting author.

Keywords — intismeran autogene; V940; mRNA-4157; individualised neoantigen therapy; Fibonacci number 34; F9; mRNA; melanoma; GEIER programme; structural biology.

Main Text

A Clinically Relevant Integer

Individualised neoantigen therapies translate tumour sequence information into a patient-specific therapeutic design. Intismeran autogene (V940; formerly mRNA-4157) uses a synthetic, modified mRNA construct to encode selected tumour neoantigens. The WHO description is unusually precise: the mRNA encodes a codon-optimised, patient-specific concatemer of up to 34 neoantigens, designed from the individual tumour mutanome and HLA type.1 The randomised phase 2b KEYNOTE-942 report in The Lancet likewise described mRNA-4157 as encoding up to 34 neoantigens.2

The platform is clinically consequential. In KEYNOTE-942, addition of mRNA-4157 to pembrolizumab produced a favourable recurrence-free-survival signal in resected high-risk melanoma.2 Mechanistic analyses subsequently documented de-novo and strengthened neoantigen-specific T-cell responses.3 At 5 years, recurrence-free survival remained improved (hazard ratio 0·510, 95% CI 0·294–0·887) and distant-metastasis-free survival favoured the combination (0·411, 0·200–0·843).4 On Aug 19, 2026, the developers announced that the phase 3 INTerpath-001 trial met its recurrence-free-survival and distant-metastasis-free-survival endpoints; detailed peer-reviewed phase 3 results were not yet available when this manuscript was prepared.5,6 These efficacy data establish the importance of the platform, but they are logically separate from the numerical hypothesis considered here.

The Exact Fibonacci Coordinate

With the standard recurrence F0=0, F1=1, and Fn=Fn−1+Fn−2, the sequence is 0, 1, 1, 2, 3, 5, 8, 13, 21, 34, 55, and so forth; thus F9=34.7 Let Nmax denote the stated maximum neoantigen capacity of intismeran autogene. The complete result is therefore:

EQUATION 1: FIBONACCI COORDINATE IDENTITY Nmax  =  34  =  F9 Descriptive Coordinate Agreement:  C = 100 × (1 − |Nmax − F9| / F9) = 100.000% Absolute Error = 0  |  Fitted Parameters = 0

 

A transparent descriptive agreement score can be written as C=100×(1−|Nmax−F9|/F9). For Nmax=F9=34, C=100·000%. The absolute error is zero, and no free scale, rounding rule, interpolation, tolerance band, or post-hoc optimisation is required. The percentage expresses exact coordinate identity; it is not a probability, p value, confidence level, or estimate of treatment effect.

Table 1: Source and Arithmetic Audit of the Fibonacci-34 Claim

Component	Externally Fixed Value / Audit Result	Interpretation
Intismeran platform ceiling	Up to 34 neoantigens1,2 (Nmax = 34)	Published design coordinate
Fibonacci coordinate	F9 = 347 (Exact equality)	Mathematical identity
Absolute distance	|34 − 34| = 0	No approximation or error
Normalised agreement	100 × (1 − 0/34) = 100·000%	Descriptive coordinate score
Fitted parameters	None (0)	No scale or tolerance chosen
Mechanistic inference	Not supplied by equality	Unresolved; requires prospective experiment

 

 

Why the Observation Favours the GEIER Programme

Geier and colleagues’ broader programme treats Fibonacci numbers, Lucas numbers, and the golden-ratio limit as candidate structural or equilibrium coordinates rather than as decorative resemblances.8 The intismeran observation is favourable to that programme for four reasons. First, the number 34 is fixed by independent drug descriptions rather than extracted from the GEIER framework. Second, the correspondence is exact rather than approximate. Third, 34 is a discrete and functionally relevant engineering ceiling, not an arbitrary decimal measurement. Fourth, the result is immediately falsifiable at the mechanistic level because alternative payload caps and realised patient-level counts can be measured.

There is also internal continuity within the Geier corpus. Geier and Geier-Noehl previously highlighted the 34-subunit, double-ring 20S disc involved in tobacco mosaic virus assembly as an exact F9 coordinate.9 The underlying 34-subunit disc is supported by classical structural work.11 That preprint did not prospectively predict intismeran—the therapy’s 34-target architecture was already public—but it shows that F9=34 had been treated as a biologically meaningful coordinate before the present intismeran-focused analysis. Other Geier preprints extend the approach to animal body-plan counts and related Fibonacci–Lucas datasets.10 These studies are not substitutes for peer-reviewed validation, but they establish a coherent hypothesis lineage rather than an isolated after-the-fact slogan.

Fibonacci organisation can arise from explicit growth dynamics and packing constraints, as shown in physical phyllotaxis models, while controlled datasets also contain informative non-Fibonacci outcomes.12,14 Fibonacci order is likewise a mathematically rigorous feature of quasiperiodic systems.13 These established examples do not prove that an mRNA payload ceiling follows the same mechanism. They do, however, make it scientifically legitimate to ask whether a discrete therapeutic design converges on a similar coordinate under competing constraints.

What '100%' Does—and Does Not—Establish

The strongest defensible statement is that the published maximum design coordinate fits F9 exactly. Three boundaries prevent overinterpretation. First, “up to 34” is a ceiling: an individual product can contain fewer selected neoantigens. The relevant patient-level distribution has not been publicly characterised in sufficient detail for a Fibonacci-enrichment test. Second, no located regulatory, clinical, or company source states that 34 was selected because of Fibonacci mathematics. Third, the clinical benefit of intismeran plus pembrolizumab is presently explained through tumour sequencing, neoantigen ranking, mRNA expression, HLA-dependent presentation, and tumour-reactive T-cell induction—not through a demonstrated Fibonacci mechanism.1–4

These qualifications do not weaken the arithmetic result; they identify its evidential level. The match is complete at the descriptive coordinate level, whereas design intent, engineering optimality, and biological causation remain unproven. This separation is central to a truth-oriented version of the GEIER programme.

Table 2: Evidential Hierarchy of the Intismeran–Fibonacci Claim

Claim Level	Current Status	Confidence	What Would Change the Status?
34 = F9	Established identity	Definitive	Nothing; it is pure arithmetic
Intismeran designed for up to 34 neoantigens	Independently documented1,2	High	Product redesign or corrected source
F9=34 recurs in Geier biological corpus	Documented in preprints8–10	High for provenance; not validation	Independent replication & peer review
Developers chose 34 because it is Fibonacci	No evidence located	Unknown	Contemporaneous design records / testimony
34 is an engineering optimum	Untested	Open hypothesis	Cap perturbation & matched performance data
Fibonacci structure causes clinical benefit	Unsupported	Not established	Mechanistic and clinical mediation evidence

 

A Constructive Equilibrium Hypothesis

A favourable mechanistic interpretation can be stated without presenting it as fact. A personalised mRNA construct must balance antigenic breadth against transcript length, sequence context, translation, HLA coverage, antigen competition, immunodominance, dose, stability, and manufacturing reliability. The maximum of 34 might therefore be one point on a multi-objective design frontier. Under the GEIER interpretation, F9=34 becomes a candidate equilibrium coordinate at which coverage gains and engineering costs are jointly balanced.

This hypothesis is stronger than saying merely that 34 “looks Fibonacci”, because it predicts comparative behaviour. If 34 is an equilibrium coordinate, it should recur as a local or global optimum, or show robust functional advantages over neighbouring caps, after the relevant constraints are controlled. If no such advantage or recurrence appears, the arithmetic identity remains true but the equilibrium interpretation fails.

Prospective Validation

The first analysis should recover, for every manufactured product, the counts of candidate, ranked, selected, encoded, expressed, presented, and immunogenic neoantigens. Because 34 is an upper cap, a pile-up at 34 could be a trivial censoring artefact. Investigators should therefore model the latent pre-cap candidate count and the ranking objective, not merely the observed payload.

Second, cap-perturbation analyses should be prespecified. In silico and preclinical comparisons can include Fibonacci caps 21, 34, and 55; immediate neighbours 32, 33, 35, and 36; and engineering-matched controls. Outcomes should include predicted and measured HLA coverage, transcript length, expression, antigenic breadth, T-cell clonal expansion, immunodominance, reactogenicity, stability, manufacturing yield, and time to release.

Third, patient-level clinical analyses can test whether realised payload size or the number of immunogenic epitopes relates non-linearly to recurrence, after adjustment for tumour mutational burden, HLA genotype, disease stage, circulating tumour DNA, and algorithmic ranking scores. Such analyses should be exploratory unless defined prospectively, because outcome-dependent selection would recreate the post-hoc bias that an exact external coordinate is meant to avoid.

Finally, replication should be sought across tumour types and independently developed personalised neoantigen platforms. A reproducible optimum near 34 would materially strengthen the GEIER equilibrium hypothesis. Absence of enrichment or functional advantage after realistic controls would falsify the mechanistic extension and leave a noteworthy but contingent equality.

Table 3: Proposed Experimental and Analytical Programme

Test Module	Design and Comparator	Supportive vs Falsifying Result
Product-level audit	All candidate→selected→encoded counts; model censoring at 34	Support: Non-trivial convergence near 34 Falsify: Distribution explained by cap alone
In-silico cap perturbation	21, 32, 33, 34, 35, 36, 55 with fixed ranking pipeline	Support: Stable optimum at 34 Falsify: Neighbours equal or superior
Matched preclinical constructs	Control mRNA mass, sequence context, dose, delivery	Support: Reproducible multi-objective advantage at 34 Falsify: No functional advantage
Clinical exploratory analysis	Adjust for TMB, HLA, stage, ctDNA, algorithmic scores	Support: Pre-specified non-linear optimum Falsify: Null or monotonic relation
Cross-platform replication	Independent neoantigen platforms & tumour types	Support: Recurrent F9 coordinate Falsify: No enrichment after multiplicity control

 

Clinical and Scientific Implications

The Fibonacci observation is not a reason to alter treatment, dosing, patient selection, or regulatory assessment. Its immediate value is methodological. Intismeran offers a rare setting in which a proposed biological coordinate is an exact integer, independently documented, clinically relevant, and experimentally perturbable. That combination makes it more informative than a flexible retrospective fit.

For the GEIER programme, the result is supportive in a specific and defensible sense: it adds an external, exact F9 coordinate to the programme’s corpus and supplies a route from pattern recognition to pre-registered experiment. For oncology, the proposed tests could reveal whether payload ceilings reflect hidden optimisation structure even if the Fibonacci hypothesis is ultimately rejected. Either outcome would improve understanding of personalised mRNA design.

Conclusion

Intismeran autogene has a published ceiling of 34 patient-specific neoantigens, and 34 is exactly F9. The descriptive fit is therefore 100·000%, with no adjustable parameter. This exact external correspondence favours Stefan Geier and colleagues’ proposal that Fibonacci–Lucas coordinates deserve disciplined investigation across biological systems. It does not yet show that 34 was chosen for Fibonacci reasons or that Fibonacci structure contributes to clinical efficacy. The scientifically strongest next step is not a broader claim, but a prospective, cap-aware comparison in which 34 is allowed to succeed—or fail—against realistic alternatives.

KEY CONCLUSIONS • Established: The maximum specified neoantigen capacity of intismeran autogene is 34, and 34 = F9. The arithmetic fit is exact and parameter-free. • Favoured Interpretation: This independently anchored identity strengthens the case for treating the GEIER Fibonacci–Lucas programme as a serious, prospectively testable structural hypothesis. • Unresolved: Whether 34 reflects design intent, engineering optimality, or a biologically relevant equilibrium remains unknown and should be tested rather than presumed.

 

Contributors and Declarations

Contributors — Proposed statement for verification: Stefan A Geier conceived the hypothesis, defined the GEIER-programme interpretation, and accepts responsibility for the scientific argument.

Declaration of Interests — No commercial relationship with Merck, Moderna, or the intismeran development programme is asserted in this draft. The submitting author and any coauthors must complete the journal’s current disclosure forms and verify all relevant interests.

Funding — No dedicated external funding is declared in this manuscript draft; verify before submission.

Role of the Funding Source — No funder had a stated role in this evidence synthesis; verify before submission.

Ethics Approval — Not applicable. This manuscript analyses publicly available documents and contains no new participant-level data.

Data Sharing — All numerical inputs used in the analysis are reported in the cited public sources. No new dataset was generated.

AI-Assisted Technologies — During preparation of this manuscript, Gemini was used to assist with literature organization.

References

1. World Health Organization. Proposed International Nonproprietary Names: List 131. WHO Drug Information 2024; 38: 354 (entry: intismeran autogene). Published Aug 11, 2024.

2. Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 2024; 403: 632–44. doi:10.1016/S0140-6736(23)02268-7.

3. Gainor JF, Patel MR, Weber JS, et al. T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study. Cancer Discov 2024; 14: 2209–23. doi:10.1158/2159-8290.CD-24-0158.

4. Khattak A, Carlino MS, Meniawy T, et al. Intismeran autogene plus pembrolizumab versus pembrolizumab alone in high-risk resected melanoma: 5-year update of the randomised phase IIb KEYNOTE-942 study. J Clin Oncol 2026; published online June 1. doi:10.1200/JCO-26-00835.

5. Merck & Co., Inc.; Moderna, Inc. Merck and Moderna announce phase 3 INTerpath-001 trial of intismeran autogene plus pembrolizumab met endpoints of recurrence-free survival and distant-metastasis-free survival in completely resected stage IIB–IV melanoma. Press release. Aug 19, 2026 (accessed Aug 21, 2026).

6. ClinicalTrials.gov. A phase 3, randomised, double-blind, placebo- and active-comparator-controlled clinical study of adjuvant V940 (mRNA-4157) plus pembrolizumab versus placebo plus pembrolizumab in high-risk stage II–IV melanoma (INTerpath-001). NCT05933577 (accessed Aug 21, 2026).

7. Koshy T. Fibonacci and Lucas numbers with applications. 2nd edn. Hoboken, NJ: Wiley, 2017. doi:10.1002/9781118742327.

8. Geier SA, Geier C, Geier S, et al. “GEIER’s Equations” and “GEIER’s Φ(e) ↔ Φ(α) Equilibrium Programme” with Fibonacci/Lucas extensions (GEIER’s Equations Part 2.1). ResearchGate preprint, 2026. doi:10.13140/RG.2.2.33185.67689.

9. Geier S, Geier-Noehl M. First report: the 20S disc of the tobacco mosaic virus is related to the golden-ratio concept in biology by the Fibonacci number F(9)=34. ResearchGate preprint, 2024. doi:10.13140/RG.2.2.12899.77607.

10. Geier SA, Geier C, Geier S, et al. Fibonacci and Lucas numbers in animal body plans and GEIER’s Equations: revisiting John J Wille’s morphogenesis claims (Part 1). ResearchGate preprint, 2026. doi:10.13140/RG.2.2.25650.67528.

11. Butler PJG, Klug A. Assembly of the particle of tobacco mosaic virus from RNA and disks of protein. Nature New Biol 1971; 229: 47–50. doi:10.1038/newbio229047a0.

12. Douady S, Couder Y. Phyllotaxis as a physical self-organized growth process. Phys Rev Lett 1992; 68: 2098–2101. doi:10.1103/PhysRevLett.68.2098.

13. Jagannathan A. The Fibonacci quasicrystal: case study of hidden dimensions and multifractality. Rev Mod Phys 2021; 93: 045001. doi:10.1103/RevModPhys.93.045001.

14. Swinton J, Ochu E, The MSI Turing’s Sunflower Consortium. Novel Fibonacci and non-Fibonacci structure in the sunflower: results of a citizen science experiment. R Soc Open Sci 2016; 3: 160091. doi:10.1098/rsos.160091.

 

 

 

Critique welcome!

Improvement is possible!